As shown in Figure 4B, the decrease in Cyclin D1 caused by SHP2 knockout was restored after MG132 treatment, thus indicating that SHP2 knockout triggered the degradation of Cyclin D1 in breast cancer cells via the proteasome-mediated proteolysis pathway (Figure 4B). Here, PTPN11 is linked to breast carcinoma.